Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024

BUY
$6.52 - $20.32 $14.3 Million - $44.7 Million
2,199,931 Added 24.28%
11,259,438 $212 Million
Q2 2023

Aug 11, 2023

BUY
$5.79 - $9.11 $182,715 - $287,484
31,557 Added 0.35%
9,059,507 $68.3 Million
Q1 2023

May 12, 2023

BUY
$7.36 - $12.72 $350,924 - $606,489
47,680 Added 0.53%
9,027,950 $72.2 Million
Q4 2022

Feb 13, 2023

BUY
$7.02 - $9.76 $1.62 Million - $2.25 Million
230,236 Added 2.63%
8,980,270 $81.3 Million
Q2 2022

Aug 11, 2022

BUY
$4.66 - $13.96 $29.4 Million - $87.9 Million
6,300,034 Added 257.14%
8,750,034 $48 Million
Q4 2021

Feb 11, 2022

BUY
$24.14 - $35.18 $12.1 Million - $17.6 Million
500,000 Added 25.64%
2,450,000 $60.9 Million
Q3 2021

Nov 12, 2021

SELL
$27.38 - $42.21 $1.37 Million - $2.11 Million
-50,000 Reduced 2.5%
1,950,000 $64.4 Million
Q1 2021

May 14, 2021

SELL
$45.96 - $68.02 $4.6 Million - $6.8 Million
-100,000 Reduced 4.76%
2,000,000 $101 Million
Q4 2020

Feb 11, 2021

SELL
$13.72 - $51.57 $5.42 Million - $20.4 Million
-395,140 Reduced 15.84%
2,100,000 $102 Million
Q3 2020

Nov 13, 2020

SELL
$10.54 - $18.47 $304,606 - $533,783
-28,900 Reduced 1.14%
2,495,140 $44.1 Million
Q2 2020

Aug 14, 2020

SELL
$10.37 - $20.64 $228,139 - $454,080
-22,000 Reduced 0.86%
2,524,040 $46 Million
Q4 2019

Feb 13, 2020

BUY
$7.2 - $13.2 $1.44 Million - $2.64 Million
200,000 Added 8.53%
2,546,040 $33.6 Million
Q1 2019

May 10, 2019

BUY
$14.24 - $22.28 $712,000 - $1.11 Million
50,000 Added 2.18%
2,346,040 $44.1 Million
Q4 2018

Feb 11, 2019

SELL
$17.86 - $28.77 $1.79 Million - $2.88 Million
-100,000 Reduced 4.17%
2,296,040 $52.7 Million
Q2 2018

Aug 10, 2018

BUY
$15.0 - $25.6 $35.9 Million - $61.3 Million
2,396,040 New
2,396,040 $37.4 Million

Others Institutions Holding SRRK

About Scholar Rock Holding Corp


  • Ticker SRRK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,640,600
  • Market Cap $2.17B
  • Description
  • Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...
More about SRRK
Track This Portfolio

Track Artal Group S.A. Portfolio

Follow Artal Group S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.